The Price Of A Vaccine With Moderna CFO David Meline

Episode Summary

Executive Summary: The episode examines Moderna’s COVID-19 vaccine as a case study in capitalism, public-private partnership, and state capacity. CFO David Modin explains how private investment, NIH collaboration, and Operation Warp Speed’s funding, logistics, and regulatory speed helped deliver a vaccine rapidly, while Bethany McLean and Luigi Zingales debate pricing, patent waivers, and whether the model can be generalized beyond wartime-like crises.

Main Topics: Moderna’s vaccine development as a capitalism success story (Priority: 5/5): The conversation frames Moderna’s COVID-19 vaccine as an example of private innovation succeeding with major public support, showing how a risky startup can scale rapidly under crisis conditions. Operation Warp Speed and government partnership (Priority: 5/5): David Modin credits federal funding, expedited regulators, military logistics, and portfolio-based backing of multiple technologies for accelerating vaccine development and manufacturing. Pricing, value, and investor returns (Priority: 5/5): The hosts and Modin discuss how to price a vaccine whose social value is enormous, balancing shareholder returns, public support, and global access with tiered pricing. Patents, manufacturing bottlenecks, and global access (Priority: 4/5): The discussion argues that patent waivers matter less than manufacturing know-how, supply chains, and production capacity, which are the real constraints on scaling vaccines. Role of expertise and revolving doors (Priority: 4/5): Monsef Slaoui’s background in vaccine development is presented as crucial to Warp Speed’s success, raising the broader issue of when industry experience in government is beneficial. Lessons for public-private partnerships and state capacity (Priority: 4/5): The hosts conclude that the vaccine rollout offers limited generalizable lessons, except that government competence, expert staffing, and logistical capacity are essential in emergencies. Long-term incentives and pandemic preparedness (Priority: 4/5): The episode closes with concern that if companies expect expropriation after taking big risks, they will invest less in future preparedness for rare but catastrophic events.

Key Arguments: Moderna’s vaccine was enabled by a decade of private R&D investment, with early work largely funded by private capital and NIH collaboration rather than direct government underwriting. Operation Warp Speed mattered because it funded late-stage trials, allowed parallel manufacturing, and coordinated regulators and military logistics to compress timelines by years. Moderna intentionally priced below estimated economic value to preserve long-term reputation, recover investment, and support global access, rather than extracting maximum short-term profit. Patent waivers were portrayed as largely symbolic because actual production is constrained by specialized manufacturing know-how, limited raw materials, and supply-chain capacity. Monsef Slaoui’s industry expertise made a major difference; the hosts argue that successful public-private partnerships require knowledgeable government leadership, not just funding. The success of Warp Speed depended on extraordinary crisis conditions and visibility; these features may not transfer well to ordinary infrastructure or industrial policy projects. If firms believe they will be expropriated after successful pandemic investment, they may be less willing to take the enormous financial risk needed to prepare for future crises.

Data Points: Vaccine efficacy: 94% - The memorable first trial result that signaled the pandemic’s end might be near. Private capital invested over 10 years: Several billion dollars - Moderna’s cumulative investment in mRNA technology before the COVID-19 vaccine launch. Company equity round: $1.4 billion - Raised in May 2020 to accelerate COVID vaccine development. Phase 3 trial cost: $1.1 billion - Estimated cost of the late-stage clinical trial for Moderna’s vaccine. Government price per dose: $15 - Initial U.S. government vaccine price agreed to by Moderna. First 100 million doses price: $10 per dose - Effective price when the government-funded trial support is taken into account. International price: $30 per dose or above - Approximate initial pricing indication for many non-U.S. customers. COVAX supply agreement: 500 million doses - Moderna’s deal with the global coalition serving low-income countries. Initial U.S. government order: 100 million doses - Early procurement commitment that included at-risk prepayment. Government/trial support: Around $6 billion - Referenced by the hosts as the overall government support received in exchange for early vaccine supply. Risk capital raised for manufacturing expansion: $1.3 billion - Moderna financing used to expand manufacturing capability before vaccine success was assured. Expected production in 2021: 800 million to 1 billion doses - Moderna’s stated production target for the year. Expected production capacity in 2022: Upwards of 3 billion doses - Moderna’s planned additional capacity expansion. Products in development: 24 - Moderna’s broader pipeline beyond COVID-19. Bioavailability of proteins before mRNA platform: About one-third - Moderna described mRNA as opening access to the other two-thirds of proteins previously unreachable by biotech drugs.

Pivotal Quotes: "I can see the end of the pandemic is on the horizon." — David Modin: His reaction to learning the vaccine trial showed 94% efficacy. "The company invested cumulatively several billion dollars over that last 10 years, and that was largely private capital." — David Modin: Moderna’s long-term private investment in mRNA technology before COVID-19. "We have socialism for the very rich, rugged individualism for the poor." — Bethany McLean: The podcast’s framing critique of how capitalism and public support often intersect.

Implications: The episode suggests pandemic-era innovation can work when private risk-taking is matched with expert public coordination. But it also warns that patent waivers, weak state capacity, or expropriation fears could undermine future investment in lifesaving technologies.